Jubilant Pharmova Ltd - 530019 - Jubilant Pharmova Announces Completion Of USFDA Audit Of Radiopharmaceuticals Manufacturing Facility At Montreal, Canada

Jubilant Pharmova zooms to 52-week high after US FDA classifies Roorkee facility as VAI

Jubilant Pharmova Ltd - 530019 - Closure Of Manufacturing Operations Of Solid Dosage Formulation Facility Of Jubilant Cadista Pharmaceuticals Inc., USA ('Jubilant Cadista'), A Subsidiary, Located At Salisbury, Maryland, USA. Further, Following The Status Change Of Jubilant Generics Limited'S ('JGL') Roorkee Facility By USFDA To VAI, The Company Expects The Exports From The Roorkee Facility To The US Market To Increase In A Meaningful And Gradual Manner.

Jubilant Pharmova Ltd - 530019 - USFDA Communication

Jubilant Pharmova Ltd - 530019 - Compliance Certificate Under Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Jubilant Pharmova Ltd - 530019 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Jubilant Pharmova Ltd - 530019 - Compliance Certificate For The Financial Year Ended March 31, 2024.

Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

Jubilant Pharmova Ltd - 530019 - Intimation Under Regulation 30

Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Updates on Acquisition